Hyperbaric Oxygen Therapy, Specialty Healthcare Platform

OVERVIEW

Confidential opportunity to acquire a medically accredited hyperbaric oxygen therapy (HBOT) provider with over a decade of operating history and a strong regional presence in the Mid-Atlantic.

The Company delivers medical-grade HBOT across both insurance-reimbursed and cash-pay segments, positioning the business at the intersection of traditional outpatient healthcare and growing consumer-driven demand for non-invasive therapeutic solutions.

The business operates through a combined operating entity and management services structure, generating approximately $405K+ in consolidated adjusted EBITDA. The model is both scalable and financeable, with clear visibility into earnings and operational performance.

INVESTMENT HIGHLIGHTS

• $405K+ Adjusted EBITDA (2025)
• ~38% EBITDA margins
• ~$1.05M revenue (operating entity)
• Balanced payor mix (~48% insurance / ~46% cash pay)
• No customer concentration
• SBA financeable profile with strong DSCR characteristics

The Company has demonstrated consistent revenue and EBITDA growth, supported by increasing patient demand and operating leverage within a largely fixed-cost infrastructure.

CAPACITY & EBITDA UPSIDE

The business currently operates below full capacity, with approximately:

• ~40 patients/day total capacity
• ~23 patients/day current peak utilization (~55–60%)

This underutilization is driven by operational factors, including limited hours and staffing—not by demand constraints.

A buyer can unlock near-term EBITDA growth through:

• Extending operating hours (evenings and weekends)
• Modest staffing additions
• Increased patient throughput

No significant capital investment is required to drive this growth.

PATIENT ECONOMICS & REVENUE MODEL

The Company operates a protocol-driven treatment model, where patients typically complete approximately 40 sessions per course of care.

This results in strong per-patient economics:

• ~$28K per insurance patient
• ~$9K per cash-pay patient

Once a patient begins treatment, revenue becomes highly visible and scheduled, providing a level of predictability not typically seen in transactional service businesses.

The hybrid payor mix provides:

• Stability through insurance reimbursement
• Margin flexibility through cash-pay services

DIFFERENTIATED CLINICAL PLATFORM

The Company is positioned as a medical-grade provider, not a wellness-only operator.

Key differentiators include:

• Accreditation by The Joint Commission
• Participation with Medicare and commercial insurance carriers
• Multiplace hyperbaric chamber (multi-patient throughput)
• Established referral network and digital presence

This positioning supports both clinical credibility and sustainable patient demand.

TRANSACTION

• Structure: Stock Sale (anticipated)
• Financing: SBA-supported
• Location: Mid-Atlantic (to be disclosed post-NDA)

The opportunity is well suited for:

• Owner-operators
• Healthcare or wellness operators
• Independent sponsors

NEXT STEPS

Qualified buyers will be provided with additional information upon execution of a confidentiality agreement, including detailed financials, operational data, and management discussions.